Edgewood Oncology

About Edgewood Oncology

Edgewood Oncology is a clinical-stage biotechnology company focused on delivering BTX-A51 to address significant unmet medical needs in cancer treatment, targeting master regulators of cancer to activate programmed cell death.

Products & Services

BTX-A51:A novel small molecule, multi-kinase inhibitor that synergistically co-targets master regulators of cancer to activate programmed cell death, showing promising clinical activity and a favorable safety profile. It targets hematologic malignancies and genetically-defined solid tumors, including GATA3-mutant breast cancer.

Specialties

Cancer treatment Multi-kinase inhibitors Hematologic malignancies Genetically-defined solid tumors GATA3-mutant breast cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2024-03-25 FD: 2024-03-25	1 investors

Series A Latest

2024-03-25

$20.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David N. Cook

Chief Executive Officer

Z

Zung Thai

Chief Medical Officer

D

Dan Janney

Managing Director

I

Isan Chen, M.D.

Co-founder, President & CEO

Y

Yinon Ben-Neriah

Professor of Immunology and Cancer Research

C

Crystal Potter

Graphic and Web Designer

View 3 more team members with Pro

Unlock Full Team Directory

Recent News